CBDV vs. ASD - Autism Spectrum Disorder
The first cannabinoid specific university study on ‘its’ effect combating Autism Spectrum Disorder (ASD) is currently being conducted at Montefiore Medical Center at the Albert Einstein College of Medicine. The cannabinoid Cannabidivarin, has demonstrated anticonvulsant activity in animals and humans. The study is funded by a $1.3m grant from the Department of Defense.
Approximately 1 in 59 kids have Autism according to the Center for Disease Control and Prevention which has been a growing concern since 2000. The number has increased from an average of 1 in 150 children per 1000 being diagnosed with ASD in the year 2000, to 1 in 59 per 1000 children being diagnosed in 2014. Certain theories have been presented, one of them being women in pregnancy being given opiates pre-labor but the numbers are not substantial.
Although the CBDV-cannabinoid specific study at the Albert Einstein College of Medicine is the first of its kind, studies of cannabinoids effects on Autism have been happening for a while. Specifically, in Israel by Dr. Raphael Mechoulam a professor at the Hebrew University of Jerusalem. Mechoulam is a pioneer that has been studying cannabinoids for over 30 years. He is responsible for the isolation of the cannabinoids anandamide, found in the brain, and 2-arachidonoy glycerin, found in the peripheral organs. Mechoulam and his team studied the effects of CBD mixed with small amounts of THC on Autism at a ratio of 20:1 yielding positive results in the calming of violent episodes, anxiety and seizures among Autistic children.
To learn more about this study visit the Children Hospital's Association and click here to donate now to Autism Awareness!